2024
Diacerein reduces inflammasome activation and SARS-CoV-2 virus replication: a proof-of-concept translational study
Carmo H, Castillo A, Bonilha I, Gomes E, Barreto J, Moura F, Davanzo G, de Brito Monteiro L, Muraro S, de Souza G, Morari J, Galdino F, Brunetti N, Reis-de-Oliveira G, Carregari V, Nadruz W, Martins-de-Souza D, Farias A, Velloso L, Proenca-Modena J, Mori M, Loh W, Bhatt D, Yellon D, Davidson S, De Oliveira P, Moraes-Vieira P, Sposito A. Diacerein reduces inflammasome activation and SARS-CoV-2 virus replication: a proof-of-concept translational study. Frontiers In Pharmacology 2024, 15: 1402032. PMID: 39434905, PMCID: PMC11491754, DOI: 10.3389/fphar.2024.1402032.Peer-Reviewed Original ResearchPeripheral blood mononuclear cellsHuman peripheral blood mononuclear cellsSARS-CoV-2 infectionSARS-CoV-2Viral replicationInflammatory responseInflammasome activationMarkers of inflammasome activationPlacebo-controlled studySuppress viral replicationBlood mononuclear cellsInfection in vitroPrimary metabolitesCOVID-19 patientsDouble-blindPrimary endpointHealthy volunteersSevere acute respiratory syndrome coronavirus 2Plasma markersAcute respiratory syndrome coronavirus 2Mononuclear cellsClinical trialsRespiratory syndrome coronavirus 2Day 2Syndrome coronavirus 2
2022
Abstract 14830: Comparative Cost-Effectiveness of Cardioprotective Glucose-Lowering Therapies for Type 2 Diabetes in a Middle-Income Country: A Bayesian Network Model
Carvalho L, Nogueira A, Antunes J, Moura F, Luchiari B, Bonilha I, Nadruz W, Gaziano M, Gaziano T, Sposito A. Abstract 14830: Comparative Cost-Effectiveness of Cardioprotective Glucose-Lowering Therapies for Type 2 Diabetes in a Middle-Income Country: A Bayesian Network Model. Circulation 2022, 146: a14830-a14830. DOI: 10.1161/circ.146.suppl_1.14830.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioGLP-1RAMiddle-income countriesType 2 diabetesCardiovascular eventsRisk of non-fatal cardiovascular eventsFollow-up >Pre-specified endpointsCohort of T2D patientsNon-fatal cardiovascular eventsGlucose-lowering therapySecondary prevention cohortAdverse cardiovascular eventsAnti-diabetic therapyRandomized clinical trialsCost-effectiveness ratioBrazilian public health systemDouble-blindGLP1-RAPublic health systemPrevention cohortProspective cohortT2D subjectsHeart failureT2D patients